The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning

Michael C. Holter, Lauren T. Hewitt, Stephanie V. Koebele, Jessica M. Judd, Lei Xing, Heather Bimonte-Nelson, Cheryl Conrad, Toshiyuki Araki, Benjamin G. Neel, William D. Snider, Jason Newbern

Research output: Contribution to journalArticle

Abstract

RASopathies are a family of related syndromes caused by mutations in regulators of the RAS/Extracellular Regulated Kinase 1/2 (ERK1/2) signaling cascade that often result in neurological deficits. RASopathy mutations in upstream regulatory components, such as NF1, PTPN11/SHP2, and RAS have been well-characterized, but mutation-specific differences in the pathogenesis of nervous system abnormalities remain poorly understood, especially those involving mutations downstream of RAS. Here, we assessed cellular and behavioral phenotypes in mice expressing a Raf1L613V gain-of-function mutation associated with the RASopathy, Noonan Syndrome. We report that Raf1L613V/wt mutants do not exhibit a significantly altered number of excitatory or inhibitory neurons in the cortex. However, we observed a significant increase in the number of specific glial subtypes in the forebrain. The density of GFAP+ astrocytes was significantly increased in the adult Raf1L613V/wt cortex and hippocampus relative to controls. OLIG2+ oligodendrocyte progenitor cells were also increased in number in mutant cortices, but we detected no significant change in myelination. Behavioral analyses revealed no significant changes in voluntary locomotor activity, anxiety-like behavior, or sociability. Surprisingly, Raf1L613V/wt mice performed better than controls in select aspects of the water radial-arm maze, Morris water maze, and cued fear conditioning tasks. Overall, these data show that increased astrocyte and oligodendrocyte progenitor cell (OPC) density in the cortex coincides with enhanced cognition in Raf1L613V/wt mutants and further highlight the distinct effects of RASopathy mutations on nervous system development and function.

Original languageEnglish (US)
Pages (from-to)e1008108
JournalPLoS genetics
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Noonan Syndrome
neuroglia
Neuroglia
mutation
cortex
learning
Learning
Mutation
mice
astrocytes
mutants
Oligodendroglia
stem cells
nervous system
Astrocytes
myelination
Stem Cells
neurodevelopment
Nervous System Malformations
conditioned behavior

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Molecular Biology
  • Genetics
  • Genetics(clinical)
  • Cancer Research

Cite this

The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. / Holter, Michael C.; Hewitt, Lauren T.; Koebele, Stephanie V.; Judd, Jessica M.; Xing, Lei; Bimonte-Nelson, Heather; Conrad, Cheryl; Araki, Toshiyuki; Neel, Benjamin G.; Snider, William D.; Newbern, Jason.

In: PLoS genetics, Vol. 15, No. 4, 01.04.2019, p. e1008108.

Research output: Contribution to journalArticle

Holter, Michael C. ; Hewitt, Lauren T. ; Koebele, Stephanie V. ; Judd, Jessica M. ; Xing, Lei ; Bimonte-Nelson, Heather ; Conrad, Cheryl ; Araki, Toshiyuki ; Neel, Benjamin G. ; Snider, William D. ; Newbern, Jason. / The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. In: PLoS genetics. 2019 ; Vol. 15, No. 4. pp. e1008108.
@article{b9a85a5d6b2b4553a13c550993a3480c,
title = "The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning",
abstract = "RASopathies are a family of related syndromes caused by mutations in regulators of the RAS/Extracellular Regulated Kinase 1/2 (ERK1/2) signaling cascade that often result in neurological deficits. RASopathy mutations in upstream regulatory components, such as NF1, PTPN11/SHP2, and RAS have been well-characterized, but mutation-specific differences in the pathogenesis of nervous system abnormalities remain poorly understood, especially those involving mutations downstream of RAS. Here, we assessed cellular and behavioral phenotypes in mice expressing a Raf1L613V gain-of-function mutation associated with the RASopathy, Noonan Syndrome. We report that Raf1L613V/wt mutants do not exhibit a significantly altered number of excitatory or inhibitory neurons in the cortex. However, we observed a significant increase in the number of specific glial subtypes in the forebrain. The density of GFAP+ astrocytes was significantly increased in the adult Raf1L613V/wt cortex and hippocampus relative to controls. OLIG2+ oligodendrocyte progenitor cells were also increased in number in mutant cortices, but we detected no significant change in myelination. Behavioral analyses revealed no significant changes in voluntary locomotor activity, anxiety-like behavior, or sociability. Surprisingly, Raf1L613V/wt mice performed better than controls in select aspects of the water radial-arm maze, Morris water maze, and cued fear conditioning tasks. Overall, these data show that increased astrocyte and oligodendrocyte progenitor cell (OPC) density in the cortex coincides with enhanced cognition in Raf1L613V/wt mutants and further highlight the distinct effects of RASopathy mutations on nervous system development and function.",
author = "Holter, {Michael C.} and Hewitt, {Lauren T.} and Koebele, {Stephanie V.} and Judd, {Jessica M.} and Lei Xing and Heather Bimonte-Nelson and Cheryl Conrad and Toshiyuki Araki and Neel, {Benjamin G.} and Snider, {William D.} and Jason Newbern",
year = "2019",
month = "4",
day = "1",
doi = "10.1371/journal.pgen.1008108",
language = "English (US)",
volume = "15",
pages = "e1008108",
journal = "PLoS Genetics",
issn = "1553-7390",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning

AU - Holter, Michael C.

AU - Hewitt, Lauren T.

AU - Koebele, Stephanie V.

AU - Judd, Jessica M.

AU - Xing, Lei

AU - Bimonte-Nelson, Heather

AU - Conrad, Cheryl

AU - Araki, Toshiyuki

AU - Neel, Benjamin G.

AU - Snider, William D.

AU - Newbern, Jason

PY - 2019/4/1

Y1 - 2019/4/1

N2 - RASopathies are a family of related syndromes caused by mutations in regulators of the RAS/Extracellular Regulated Kinase 1/2 (ERK1/2) signaling cascade that often result in neurological deficits. RASopathy mutations in upstream regulatory components, such as NF1, PTPN11/SHP2, and RAS have been well-characterized, but mutation-specific differences in the pathogenesis of nervous system abnormalities remain poorly understood, especially those involving mutations downstream of RAS. Here, we assessed cellular and behavioral phenotypes in mice expressing a Raf1L613V gain-of-function mutation associated with the RASopathy, Noonan Syndrome. We report that Raf1L613V/wt mutants do not exhibit a significantly altered number of excitatory or inhibitory neurons in the cortex. However, we observed a significant increase in the number of specific glial subtypes in the forebrain. The density of GFAP+ astrocytes was significantly increased in the adult Raf1L613V/wt cortex and hippocampus relative to controls. OLIG2+ oligodendrocyte progenitor cells were also increased in number in mutant cortices, but we detected no significant change in myelination. Behavioral analyses revealed no significant changes in voluntary locomotor activity, anxiety-like behavior, or sociability. Surprisingly, Raf1L613V/wt mice performed better than controls in select aspects of the water radial-arm maze, Morris water maze, and cued fear conditioning tasks. Overall, these data show that increased astrocyte and oligodendrocyte progenitor cell (OPC) density in the cortex coincides with enhanced cognition in Raf1L613V/wt mutants and further highlight the distinct effects of RASopathy mutations on nervous system development and function.

AB - RASopathies are a family of related syndromes caused by mutations in regulators of the RAS/Extracellular Regulated Kinase 1/2 (ERK1/2) signaling cascade that often result in neurological deficits. RASopathy mutations in upstream regulatory components, such as NF1, PTPN11/SHP2, and RAS have been well-characterized, but mutation-specific differences in the pathogenesis of nervous system abnormalities remain poorly understood, especially those involving mutations downstream of RAS. Here, we assessed cellular and behavioral phenotypes in mice expressing a Raf1L613V gain-of-function mutation associated with the RASopathy, Noonan Syndrome. We report that Raf1L613V/wt mutants do not exhibit a significantly altered number of excitatory or inhibitory neurons in the cortex. However, we observed a significant increase in the number of specific glial subtypes in the forebrain. The density of GFAP+ astrocytes was significantly increased in the adult Raf1L613V/wt cortex and hippocampus relative to controls. OLIG2+ oligodendrocyte progenitor cells were also increased in number in mutant cortices, but we detected no significant change in myelination. Behavioral analyses revealed no significant changes in voluntary locomotor activity, anxiety-like behavior, or sociability. Surprisingly, Raf1L613V/wt mice performed better than controls in select aspects of the water radial-arm maze, Morris water maze, and cued fear conditioning tasks. Overall, these data show that increased astrocyte and oligodendrocyte progenitor cell (OPC) density in the cortex coincides with enhanced cognition in Raf1L613V/wt mutants and further highlight the distinct effects of RASopathy mutations on nervous system development and function.

UR - http://www.scopus.com/inward/record.url?scp=85065681400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065681400&partnerID=8YFLogxK

U2 - 10.1371/journal.pgen.1008108

DO - 10.1371/journal.pgen.1008108

M3 - Article

C2 - 31017896

AN - SCOPUS:85065681400

VL - 15

SP - e1008108

JO - PLoS Genetics

JF - PLoS Genetics

SN - 1553-7390

IS - 4

ER -